Stocks making the biggest moves midday: Microsoft, SpaceX, Vaxcyte, Banco Bradesco, DraftKings & more

PTC surged 33% after agreeing to be acquired by Schneider Electric for $205 per share, valuing its equity at more than $22 billion; closing is expected by Q3 2027. Vaxcyte rose about 30% on positive Phase 3 vaccine results, while Brazilian stocks rallied after Flavio Bolsonaro edged Lula by about 2 percentage points, with EWZ up 13%. Moves were mixed across the roundup: Sphere Entertainment fell 12% on a downgrade and softer demand, and Millrose Properties and Lennar each dropped roughly 6% after a short report questioned investment economics and strategic influence.

Analysis

The strongest signals here are event-specific, not a broad risk-on read. TSMC’s possible role in Terafab creates a potential foundry and execution advantage, but discussions do not establish orders, capacity, or economics; Intel’s participation also means its share-price weakness should not yet be read as proof it is excluded. The key 1–3 month evidence is a disclosed commercial commitment or credible production timeline.

PTC’s deal price gives the stock an anchor, but the long gap to expected closing leaves exposure to financing, approvals, and termination risk. Without the current price and deal conditions, the spread cannot be assessed as an attractive arbitrage. For Vaxcyte, topline comparability is not equivalent to regulatory approval or commercial uptake; the full dataset and FDA path matter more than the initial pop. DraftKings’ prediction-market revenue and market-making estimates are analyst projections, with regulatory permissions and potential substitution for sportsbook activity as important offsets.

Brazil’s rally embeds expectations about policy and risk premia, not just the election result. Any reversal in the candidate’s prospects, coalition support, or fiscal-policy signals could unwind foreign-flow-driven gains, while MELI also has company-specific exposure beyond Brazil. Contrarian read: upgrading narratives and headline moves are not catalysts by themselves; near-term price action may have outrun verifiable earnings changes in several names.

Key Decisions for Investors

• TSM/INTC: Consider a small, catalyst-driven relative-value long TSM versus short INTC only if further reporting confirms TSMC has a defined Terafab role and Intel lacks comparable economics. If no contracts or production details emerge, close rather than treat the initial move as a durable share shift.
• PTC: Do not chase the takeover jump. First compare the live share price with the $205 consideration and verify financing, approvals, termination rights, and expected timing; only consider deal-arbitrage exposure if the annualized spread compensates for the extended close risk.
• PCVX: Avoid extrapolating topline results into a commercial forecast. Reassess on release of detailed trial data and regulatory guidance; efficacy, safety, and filing milestones are the falsifiers for the bullish read-through versus PFE and MRK.
• Brazil exposure: Avoid adding to the post-election gap in EWZ or ITUB/BBD until policy direction and coalition support are clearer. For MELI, separate Brazil-driven valuation risk from company-specific operating trends; a reversal in political odds or fiscal signals is a trim/hedge trigger.